RxDoctor Payments Data

Khaled Eissa, MD

Critical Care Medicine · Burlington, MANPI 1124257928

Payments from drug & device makers

$423in general payments, 2019–2025

Across 22 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$176
  • AstraZeneca$61
  • Boehringer Ingelheim$59
  • Mylan Specialty L.p.$44
  • Pfizer$20
  • United Therapeutics Corporation$20
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$41197%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$423 in reported general payments places this provider in the 55th percentile of 158 critical care medicine providers in Massachusetts.

See all critical care medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$90,422
Medicare patients
276
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil13$351,532
OfevNintedanib Esylate11$142,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$108,889
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr175$94,615
Breo ElliptaFluticasone/Vilanterol32$20,364
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$15,770
Spiriva RespimatTiotropium Bromide14$10,922
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$8,142
DuleraMometasone/Formoterol11$8,077
SymbicortBudesonide/Formoterol Fumarate16$5,442
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,569
Albuterol Sulfate HfaAlbuterol Sulfate137$3,447
Azithromycin78$825
Montelukast Sodium44$723
Fluticasone Propionate15$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$176$223,868330 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$59$169,00047 claims
AstraZenecaBevespi Aerosphere, Symbicort$61$13,58535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 158 critical care medicine providers in Massachusetts.

Other critical care medicine in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →